A Study of Peripheral Oxygen Saturation Measured by a Novel Pulse Oximeter under Hypoxic Conditions in Healthy Japanese Volunteers

Naoyuki Otani1,5,*, Kenshi Nakagawa2, Hirokazu Wakuda1, Masae Kuranari3, Aritoshi Eto4, Hideo Kudo1,5, Hiromitsu Imai5, and Naoto Uemura1,3,5

1Department of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine, Oita, Japan
2Oita Red Cross Hospital, Oita, Japan
3General Clinical Research Center, Oita University Hospital, Oita, Japan
4HOKS Co., Ltd, Oita, Japan
5Clinical Pharmacology Center, Oita University Hospital, Oita, Japan

Abstract

Pulse oximetry is a non-invasive technology for continuous monitoring of arterial oxygen saturation that has become a standard tool for assessment of oxygenation and respiratory function. Various pulse oximeters have been developed over the years. However, to date not all parts of pulse oximeters are made in Japan, and there are no established methods for pulse oximetry assessment under hypoxia. Therefore, we attempted to create hypoxic conditions via a novel method and measure peripheral oxygen saturation using a new pulse oximeter manufactured in Japan.

Keywords: Hypoxia; Pulse Oximeter; Gas; SpO2; Peripheral Oxygen Saturation

Introduction

Pulse oximetry is a noninvasive technology for continuous monitoring of arterial oxygen saturation and has become a standard tool for assessment of oxygenation and respiratory function in patients [1-3]. Healthcare providers routinely measure oxygen saturation (SpO2) by pulse oximetry to obtain accurate oxygen saturation data for the detection of hypoxemia.

The technique of pulse oximetry has been described previously [4]. Using spectrophotometric methodology, pulse oximetry measures SpO2 by illuminating the skin and measuring changes in light absorption of oxygenated blood (oxyhemoglobin) and deoxygenated blood (reduced hemoglobin) using two light wavelengths: 660 nm (red) and 940 nm (infrared) [4,5]. Pulse oximeters use transmission sensors in which the light emitter and detector are on opposing surfaces of the tissue bed. To date these sensors have been manufactured in other countries; however, the HOKS Co., Ltd (Oita, Japan) has now built sensors for its new pulse oximeter. Our aim in this study is to evaluate whether this novel Japanese probe can secure measurement accuracy equivalent to the SpO2 measured by conventional probes under hypoxic conditions of our devising.

The accuracy of SpO2 depends on two factors: the validity of the calculating formula (the calibration curve) and deviations from the calculating formula. For this reason, JIS T 80601-2-61, the International Standard of pulse oximetry equipment, requires each manufacturer to conduct controlled desaturation studies on human subjects and validate the SpO2 accuracy in comparison with “gold standard (SpO2),” which is intended to include the validation of these two factors. In the JIS T 80601-2-61, the SpO2 value determined by analyzing arterial blood samples with a hemoximeter is deemed the
reference value, and SpO2 accuracy of the pulse oximetry equipment is stated in terms of the RMS (root-mean-square) difference between measured value (SpO2) and reference value (SpO2). We will examine the difference between the SpO2 measured by a standard device and the SpO2 measured by the new device made by HOKS. This RMS difference means that two-thirds of the SpO2 values measured by a pulse oximeter can be expected to fall within the range of RMS. All pulse oximeters and patient monitors with HOKS SpO2 technology are designed and manufactured to meet the same specifications for SpO2 accuracy in our simulation.

One can create a low-oxygen environment by, for example, climbing to high altitude or breathing a low-oxygen gas. By manufacturing a gas-mixing device, we were able to create a hypoxic condition (oxygen concentration: 2.5% to 10%) under low-oxygen inhalation at bedside. The aims of this study are to obtain approval for the new pulse oximeter and establish a novel method for oximetry assessment under hypoxic conditions.

**Primary Endpoints**

The primary endpoints of this study are assessment of the peripheral oxygen saturation measured by a novel pulse oximeter under hypoxic conditions in healthy volunteers, the comparison of the novel device and the standard device, and safety.

**Eligibility Criteria**

To participate in the study, the volunteers will be required to fulfill the following criteria: (1) aged 20–45 years, (2) having body mass index (BMI) 18.5–30.0, and (3) having provided written consent to participate in the study. The exclusion criteria are as follows: volunteers (1) with SpO2 of less than 94% in room air; (2) with chronic obstructive pulmonary disease, asthma, sleep apnea syndrome, methemoglobinemia, or lung cancer; (3) with a history of pneumothorax or any thoracic surgery; (4) deemed unsuitable for measurement, e.g., digital anomalies such as absent index or middle finger; and (5) having abnormal data for any examinations with the goal of treatment.

**Figure 1:** Overview of hypoxic condition device.

**Treatment Methods**

**Study design.** After the acquisition of written consent, the subjects will be screened. The subject mounts a mask, produced by Koken Ltd (Tokyo, Japan), which covers the nose and mouth, and starts to inhale a mixture of O2 and N2 through a respiratory gas blender (KOFLOC Corp.) (Figure 1). The subject undergoes SpO2 assessment while breathing the O2/N2 mixture (oxygen concentration: 2.5% to 10%) (Figure 2). The subject mounts the standard device on the forefinger of the right hand, and the test device on the middle finger of the right hand and the forefinger and middle finger of the left hand. The
subject inhales the gases and waits 5 minutes. We check that the SpO₂ value of the standard pulse oximeter is at steady state and record it. The value measured by the new pulse oximeter is also recorded in the same manner. The measurements are repeated every 30 seconds for a total of 10 measurements (Figure 1). If the decline of SpO₂ is less than 2%, we stop the measurement and proceed to the next hypoxic stage. For safety reasons, if the measured the SpO₂ of the standard pulse oximeter is 75% or less, the subsequent experiments are discontinued.

Figure 2: Trial flowchart.

**Ethics considerations.** This study was approved by Oita University Faculty of Medicine Institutional Review Board on February 25, 2019 (reference no. B18-008). The study will be conducted in compliance with the Declaration of Helsinki in conjunction with our hospital’s Ethical Guidelines for Medical and Health Research Involving Human Subjects. This study was registered in the Clinical Trial Registry (UMIN-CTR) on March 11, 2019 (UMIN000036103). In connection with this study, we have carried liability insurance as a compensation measure for eventual health damage caused to the subjects.

**Statistical Considerations**

**Sample size.** The number of registered patients was planned as n = 3. As the purpose of this study is to assess the accuracy and safety of the novel pulse oximeter for development, and the number of these devices is limited, the number of patients was based on feasibility rather than on testing the statistical hypothesis.

**Statistical analysis.** The number of patients enrolled in the study and who are observed using the investigational device is considered an analysis set. The frequency distribution of the ratings of each evaluation item will be calculated. The SpO₂ of mean, standard deviation, count, and RMS are provided for each oximeter’s bias in the following ranges of SpO₂: 70%–80% and 80%–100%.

The RMS error is calculated as follows:

$$\text{RMS Error} = \sqrt{\frac{\sum (\text{SpO}_2 - \text{SaO}_2)^2}{n}}$$

**Conclusion**

For the development of a novel pulse oximeter in Japan, it has become necessary to devise an evaluation method for hypoxia. However, at present very few devices described in previous studies can create hypoxic conditions. The present study aims to develop and obtain approval for a new pulse oximeter using a novel method under hypoxia.

**Funding**

This work was financially supported by Oita Medical Robots and Equipments Industry Council and HOKS Co., Ltd for “the medical-engineering collaboration research development subsidized project” in fiscal year 2018.
Conflict of interest

The authors declare no conflicts of interest.

Acknowledgments

We wish to thank the staff of Eto Oxygen Co., Ltd. and Clinical Engineering Research Center for their helpful support. We thank Hugh McGonigle, from Edanz Group (www.edanzediting.com/ac), for editing a draft of the manuscript.

References


This manuscript was peer-reviewed
Mode of Review: Single-blinded
Academic Editor: Dr. MA Jahangir